


RÉPUBLIQUE DU CAMEROUN Paix-Travail-Patrie MINISTÈRE DE LA SANTÉ PUBLIQUE SECRETARIAT GENERAL CELLULE DES INFORMATIONS SANITAIRES	 MINSANTE	REPUBLIC OF CAMEROON Peace-Work-Fatherland MINISTRY OF PUBLIC HEALTH SECRETARIAT GENERAL HEALTH INFORMATION UNIT
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NATIONAL HEALTH INFORMATION SYSTEM

MONTHLY PROGRESS REPORT OF INTEGRATED HEALTH CENTRES AND OTHERS RANKING AS SUCH

- MPR 3 -

Year :	Month :
---------------	----------------

I. IDENTIFICATION OF THE HEALTH FACILITY

Region :	Division :	Sub-Division :
Health District:	Health area :	
Name of the health facility:		
Status : Public <input type="checkbox"/> Public related <input type="checkbox"/> Parapublic <input type="checkbox"/> Denominational private <input type="checkbox"/> Private non-profit <input type="checkbox"/> Private for-profit <input type="checkbox"/>		
Telephone number of the health facility:		
E-mail :		
Location (Town/Village/Neighbourhood) :		
Data entry date into DHIS2 :	____/____/____	
Data Manager name :		
Data Manager telephone number :		
Name of Head of health facility		
<i>Stamp of the health facility</i>	<i>Signature of the Head of health facility</i>	

II. REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH)

II.1 MATERNAL HEALTH

II.1.1 ANTENATAL CONSULTATIONS	10-14 years	15-19 years	> 19 years
1. Number of pregnant women below 15 years received during the month			
2. Number of pregnant women received for ANC I (1 st contact) during the month			
3. Number of pregnant women who attended their first ANC before 16 weeks			
4. Number of pregnant women received for ANC 4 and above during the month			
5. Number of pregnant women who received the first IPT dose			
6. Number of pregnant women who received the third IPT dose (complete IPT)			
7. Number of pregnant women who received at least two doses of Tetanus vaccine during the current pregnancy consulted during the month			
8. Number of pregnant women who received the 1 st dose of Tetanus vaccine during the month			
9. Number of pregnant women who received the 2 nd dose of Tetanus vaccine during the month			
10. Number of pregnant women who received the 3 rd dose of Tetanus vaccine during the month			
11. Number of pregnant women who received the 4 th dose of Tetanus vaccine during the month			
12. Number of pregnant women who received the 5 th dose of Tetanus vaccine during the month			
13. Number of pregnant women who received the 1 st dose of Tetanus Diphtheria vaccine during the month			
14. Number of pregnant women who received the 2 nd dose of Tetanus Diphtheria vaccine during the month			
15. Total number of women received for ANC during the month whose blood pressure was measured			
16. Total number of women received for ANC who did the syphilis test			
17. Number of syphilis cases diagnosed in pregnant women in ANC during the month			
18. Number of syphilis cases in pregnant women treated in ANC during the month			
19. Number of pregnant women screened for hepatitis B during the month			
20. Number of pregnant women who tested positive to hepatitis B during the month			

II.1.2 DELIVERIES, EMERGENCY OBSTETRIC AND NEONATAL CARE	10-14 years	15-19 years	> 19 years
21. Total number of deliveries in the health facility during the month			
22. Total number of deliveries recorded within the community during the month			
23. Number of women who benefited from AMTSL during the month			
24. Number of deliveries with obstetric complications :			

Number of cases of haemorrhage			
Number of cases of prolonged labour/dystocia			
Number of cases of preeclampsia/eclampsia			
Number of cases of uterine ruptures			
Number of puerperal infections cases			
25. Number of obstetric complications cases managed or referred during the month			
26. Number of complicated abortion cases recorded in the health facility during the month			
27. Number of maternal deaths recorded in the health facility during the month			
28. Number of maternal deaths recorded within the community during the month			
29. Number of maternal deaths audited during the month			
28. Number of abortion-related deaths recorded during the month			
29. Number of women who started a family planning method in immediate postpartum during the month			

II.1.3 POSTNATAL CONSULTATION	10-14 years	15-19 years	> 19 years
30. Number of women who started a family planning method during the postpartum period during the month			
31. Number of women who delivered and spent at least 48 hours in the health facility during the month			
32. Number of couples (mother and newborn) who received at least one postnatal consultation within 48 hours following delivery			
33. Number of couples (mother and newborn) who received one postnatal consultation between six and ten days following delivery			
34. Number of women who received Vitamin A in postpartum during the month			

II.1.4 BIRTHS	M	F
35. Number of live births recorded in the health facility during the month		
36. Number of live births recorded in the community during the month		
37. Number of birth declarations forwarded to the Civil Status Centre during the month		
38. Number of premature live births recorded during the month		

39. Number of premature or low weight newborns (below 2500 g) who were administered kangaroo care	
40. Number of new cases of sick newborns received during the month (fever, jaundice, refuses to breastfeed, lethargy...)	
41. Number of new cases of sick newborns referred	
42. Number of cases of birth asphyxia	
43. Number of cases of birth asphyxia resuscitation (mask and valve)	
44. Number of live births weighing below 2500g recorded	
45. Number of still births recorded in the health facility	
46. Number of newborn deaths that occurred during the first 24 hours of life	
47. Number of neonatal deaths (0 - 28 days) recorded in the HF during the month	

II.1.5 FAMILY PLANNING		
48. Number of new users (additional clients)		
49. Number of users who chose one of the following contraceptive method during the month	New	Old
<i>Progestative pill</i>		
<i>Oestroprogestogenic pill</i>		
<i>Morning-after pill</i>		
<i>Intramuscular Injections (Depo provera,...)</i>		
<i>Subcutaneous Injections (Sayana Press)</i>		
<i>Implants</i>		
<i>IUD</i>		
<i>VSC : voluntary surgical contraception (tubal ligation, vasectomy,...)</i>		
<i>Male condom</i>		
<i>Female condom</i>		
<i>Natural method</i>		

II.2 SCREENING FOR GENESIC CANCERS AND OBSTETRIC FISTULA	
50. Number of women aged between 30 - 49 years screened for cervical cancer	
51. Number of suspected and referred cancer cases (breast, cervix)	
52. Number of obstetric fistula cases screened and referred	

II.3 PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV

53. Number of pregnant women who did their first HIV test during the current pregnancy during the month.	
54. Number of pregnant women who took their HIV test results during the month	
55. Number of pregnant women who did their first HIV test and tested positive during the month	
56. Number of pregnant women known to be HIV positive during their first ANC	
57. Number of pregnant women who tested negative during their first ANC visit, who were retested for HIV during the second, third or fourth ANC during the month	
58. Number of pregnant who tested negative during their first ANC visit, who were retested for HIV and diagnosed HIV positive during the second, third or fourth ANC during the month	
59. Number of male partners of pregnant women received during the month who were screened for HIV	
60. Number of male partners of pregnant women received during the month who tested HIV positive	
61. Number of HIV positive pregnant women who received Co-trimoxazole prophylaxis during the month	
62. Number of HIV positive pregnant women who started ARV triple therapy on site during the month	
63. Number of HIV positive pregnant women already on triple therapy at the time of their first ANC during the month	
64. Number of HIV positive pregnant women in whom the search for clinical signs of TB was conducted during the month	
65. Number of pregnant women who did their first HIV test during the current pregnancy in the labour room during the month.	
66. Number of pregnant women who did their first HIV test during the current pregnancy in the labour room and were diagnosed HIV positive during the month	
67. Number of pregnant women who tested negative in ANC who were retested for HIV in the labour room during the month	
68. Number of pregnant women who tested negative during ANC who were retested and diagnosed HIV positive in the labour room during the month	
69. Number of pregnant women tested HIV positive in the labour room and who initiated ART during the month	
70. Number of women who gave birth in the HF during the month	
71. Number of HIV positive women who gave birth in the HF during the month	
72. Number of children born to HIV positive mothers in the HF during the month	
73. Number of children born to HIV positive mothers who started postpartum Nevirapine prophylaxis within 72 hours during the month	
74. Number of HIV positive women who gave birth out of the HF and came with their babies within 72 hours following delivery during the month	
75. Number of women who started a family planning method during postpartum during the month	
76. Number of HIV positive women who started a family planning method during postpartum during the month	

II.3 PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV	
77. Number of children born to HIV positive mothers received for follow-up consultation between 6 and 10 days after birth during the month	
78. Number of children born to HIV positive mothers received for follow-up consultation between 6 and 8 weeks during the month	
79. Number of children born to HIV positive mothers who started Cotrimoxazole from 6 weeks postpartum during the month	
80. Number of children born to HIV positive mothers screened by PCR between 6 and 8 weeks during the month	
81. Number of children born to HIV positive mothers diagnosed by PCR between 6 - 8 weeks during the month	
82. Number of children born to HIV positive mothers screened by PCR between 8 weeks - 9 months during the month	
83. Number of children born to HIV positive mothers diagnosed by PCR between 8 weeks - 9 months during the month	
84. Number of children born to HIV positive mothers still on exclusive breastfeeding at 6 months of age during the month	
85. Number of children born to HIV positive mothers seen at the 9-month visit during the month	
86. Number of children born to HIV positive mothers seen at the 9-month visit who are up to date with their vaccination	
87. Number of children born to HIV positive mothers who tested positive by serology between 9 -18 months and tested by PCR during the month	
88. Number of children born to HIV positive mothers, who tested positive by serology between 9 -18 months and confirmed positive by PCR during the month	
89. Number of children born to HIV positive mothers confirmed HIV positive by PCR who initiated ART during the month	

III. CHILD AND ADOLESCENT HEALTH

III.1 CHILD IMMUNIZATION (EPI) ACTIVITIES / COMMUNICATION FOR IMMUNIZATION	0 - 11 months Number of sessions		12-59 months Persons sensitized
	Planned	Achieved	
90. Vaccination in fixed strategy			
91. Vaccination in advanced/mobile strategy			
92. Announcement by a town crier or sensitization with a megaphone			
93. Educative talk in health facilities			
94. Educative talks in the community/associations			
95. Communication in places of prayer			
96. Communication with traditional healers			
97. Search for the lost to follow up (number to be looked for and number found)			

III.2 IMMUNIZATION OF CHILDREN (EPI)	0 - 11 months				12-59 months	Refugees
	Fixed		Advanced/Mobile			
	M	F	M	F		
98. Number of children who received BCG vaccine						
99. Number of children who received HepB0 vaccine						
100. Number of children who received OVP0 vaccine						
101. Number of children who received OVP 1 vaccine						
102. Number of children who received OVP 2 vaccine						
103. Number of children who received OVP3 vaccine						
104. Number of children who received PVI vaccine						
105. Number of children who received DTP+ HepB1+Hib1 (Penta 1) vaccine						
106. Number of children who received DTP+ HepB3+Hib2 (Penta 2) vaccine						
107. Number of children who received DTP+ HepB3+Hib3 (Penta 3) vaccine						
108. Number of children who received the 1 st dose of the pneumonia vaccine (PCV-13-1)						
109. Number of children who received the 2 nd dose of the pneumonia vaccine (P PCV-13-2)						
110. Number of children who received the 3 rd dose of pneumonia vaccine (PCV-13-3)						
111. Number of children who received Rota 1						
112. Number of children who received Rota 2						
113. Number of children who received the 1 st dose of measles/rubella vaccine						
114. Number of children who received the 2 nd dose of measles/rubella vaccine						
115. Number of children immunized against yellow fever						
116. Number of children who received MenA vaccine						
117. Number of children who received Vitamin A (6-11 months)						

III.3 IMMUNIZATION OF ADOLESCENTS (PEV)	Fixed	Advanced/Mobile	Refugees
118. Number of girls aged 9-13 years who received the 1 st dose of HPV vaccine			
119. Number of girls aged 9-13 years who received the 2 nd dose of HPV vaccine			
120. Number of girls aged 9-13 years who received the 3 rd dose of HPV vaccine			

III.4 STORAGE OF VACCINES AND WASTE MANAGEMENT

I21. Minimum temperature recorded	
I22. Maximum temperature recorded	
I23. Number of low temperature detectors (Number of temperature > +2°C)	
I24. Number of high temperature detectors (Number of temperature > +8°C)	
I25. Number of safety boxes used	
I26. Number of safety boxes destroyed	

III.2 Surveillance of AEFIs (Adverse Effects Following Immunization)

Type of AEFI	Number	Antigen	Batch No.	Expiry date
I27. Fever > 48 hours				
I28. Rash				
I29. Adenopathies				
I30. Abscess				
I31. Anaphylactic shock				
I32. Others (list them)				

III.2 INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS

I33. Number of diarrhea cases recorded in children aged below five years (0 to 59 months)	
I34. Number of children from 0 - 59 months who received ORS + ZINC (oral rehydration salts and Zinc) therapy against diarrhea	
I35. Number of children aged 0 - 59 months with pneumonia	
I36. Number of children aged 0 - 59 months with pneumonia who received antibiotic treatment	
I37. Number of children who received one dose of Mebendazole during the month	

IV. DISEASE CONTROL

IV.1 COMMUNICABLE DISEASE CONTROL

IV.1.1 HIV/AIDS CONTROL, VOLUNTARY COUNSELLING AND TESTING OF HIV AND COMPREHENSIVE MANAGEMENT OF PLWHIV	< 1year			1 - 3 years			4 -9 years			10 -14 years			15 -19 years			20-24 years			25-49 years			>= 50years			TOTAL		
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
138. Number of old PLWHIV on ART expected during the month																											
139. Total number of old PLWHIV on ART who received treatment during the month																											
140. Total number of new PLWHIV on ARV who received treatment during the month																											
141. Total number of PLWHIV on ART who received their treatment during the month																											
142. Number of PLWHIV on 1 st line ART who received their treatment during the month																											
143. Number of PLWHIV on 2 nd line ART who received their treatment during the month																											
144. Number of PLWHIV on ART who switched from 1 st line to 2 nd line ART during the month																											
145. Number of PLWHIV who received Cotrimoxazole during the month																											
146. Number of PLWHIV in whom the clinical signs de of tuberculosis were investigated and documented during the month																											
147. Number of PLWHIV who initiated treatment 12 months before the current month																											
148. Number of PLWHIV who did the CD4 count (medical follow up at 12 months) during the month																											
149. Number of PLWHIV who did the viral load test 12 months after treatment initiation during the month																											

IV.1.2 HIV/AIDS CONTROL, VOLUNTARY COUNSELLING AND TESTING OF HIV AND COMPREHENSIVE MANAGEMENT OF PLWHIV	< 1 year			1 - 3 years			4 - 9 years			10 - 14 years			15 - 19 years			20-24 years			25-49 years			≥ 50 years			TOTAL		
	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
150. Number of persons on ART presenting a suppression of the viral load 12 months after treatment initiation during the month																											
151. Number of PLWHIV still on ART 12 months after treatment initiation during the month																											
152. Number of deaths of PLWHIV reported during the month																											
153. Number of PLWHIV who did not collect their treatment during the month																											
154. Number of PLWHIV absent during the previous month who were found and for whom treatment was reinitiated																											
155. Occasional assistance (PLWHIV not followed up at the ATC/Management Centre but who came to collect their treatment during the month)																											
156. Number of cases of exposure to blood and other biological fluids (BEA) who received ART																											

IV.1.3 VOLUNTARY TESTING OF HIV/AIDS

		Number of persons counselled during the month	Number of persons tested during the month	Number of persons who took their results during the month	Number of persons tested positive during the month	Number of persons tested positive referred to the management unit during the month	Number of unspecified results during the month
≤ 9 years	M						
	F						
	Total						
10-14 years	M						
	F						
	Total						
15-19 years	M						
	F						
	Total						
20-24 years	M						
	F						
	Total						
25- 29 years	M						
	F						
	Total						
30-34 years	M						
	F						
	Total						
35-39 years	M						
	F						
	Total						
40-44 years	M						
	F						
	Total						
45-49 years	M						
	F						
	Total						
≥ 50 years	M						
	F						
	Total						
Total	M						
	F						
	Total						

IV.2 MALARIA CONTROL	< 5years	≥ 5 years (excluding PW)	Pregnant women (PW)
157. Number of Long Lasting Insecticide-treated Nets (LLINs) distributed			
158. Number of cases suspected for uncomplicated malaria (clinical uncomplicated malaria)			
159. Number of cases suspected for severe malaria			
160. Number of Rapid Diagnostic Tests (RDT) done by health staff			
161. Number of positive Rapid Diagnostic Tests (RDT)			
162. Number of thick smears tests done by the health staff			
163. Number of positive thick smears			
164. Number of fever cases suspected to be uncomplicated malaria for which a confirmation test was not done (RDT or thick smear)			
165. Number of cases suspected to be severe malaria for which a confirmation test was not done (RDT or thick smear)			
166. Number of uncomplicated malaria cases with positive RDT			
167. Number of uncomplicated malaria cases with positive thick smear			
168. Number of severe malaria cases with positive RDT			
169. Number of severe malaria cases with positive thick smear			
170. Number of hospitalizations for severe malaria confirmed (with RDT or microscopy)			
171. Number of confirmed uncomplicated malaria cases treated by the health staff with ASAQ combination			
172. Number of confirmed uncomplicated malaria cases treated by the health staff with ACT other than ASAQ			
173. Number of confirmed severe malaria cases treated with injectable artesunate			
174. Number of confirmed severe malaria cases treated with injectable artemether			
175. Number of confirmed severe malaria cases treated with injectable quinine			
176. Number of fever cases suspected to be uncomplicated malaria with negative RDT who received antimalarial treatment			
177. Number of uncomplicated malaria cases who received antimalarial treatment without a confirmation test (RDT or thick smear)			
178. Number of fever cases reported by community health workers			
179. Number of Rapid Diagnostic Tests (RDT) done and interpreted by community health workers in fever cases			
180. Number of uncomplicated malaria cases confirmed with RDT by community health workers (pregnant women excluded)			
181. Number of confirmed cases of uncomplicated malaria (pregnant women excluded) treated by CHWs based on the national policy (with ASAQ)			
182. Number of cases referred (severe malaria or negative Rapid Diagnostic Test) to the health facility by community health workers			
183. Number of people who died for confirmed malaria			

IV.1.1 TUBERCULOSIS CONTROL	Smear-positive Pulmonary Tuberculosis (PTB+)			Smear-negative Pulmonary Tuberculosis (PTB-)			Extra pulmonary Tuberculosis			TOTAL
	0-4 years	5-14 years	15 years and +	0-4 years	5-14 years	15 years and +	0-4 years	5-14 years	15 years and +	
184. Number of suspected and referred cases										
185. Number of new cases										
186. Number of relapse cases										
187. Number of retreatment cases										
188. Number of treatment failure										
189. Number of patients cured / Treatment completed										
190. Number of patients lost to follow up										
191. Number of patients transferred										
192. Number of TB patients who did the HIV test (with results available in the logbook)										
193. Number of TB patients tested positive for HIV										
194. Number of HIV positive TB patients on ARVs										
195. Total number of drug resistant TB patients										
196. Number of TB-related deaths										

IV.2 NON COMMUNICABLE DISEASES CONTROL						
Diseases	New cases	Deaths		Diseases	New cases	Deaths
197. Hypertension				198. Sickle cells		
199. Diabetes				200. Gastric ulcer		
201. Stroke				202. Chronic visual impairment		
203. Asthma				204. Chronic hearing impairment		
205. Epilepsy				206. Traumas		
207. Road accidents				208. Mental disorders		
209. Rheumatisms				210. Oral diseases		
211. Domestic violence				212. Rape		

IV.3 NEGLECTED TROPICAL DISEASES CONTROL

Diseases	New cases	Deaths
213. Onchocerciasis		
215. Trachoma		
217. Leprosy		
219. Buruli Ulcer		
221. Human African Trypanosomiasis (HAT)		
223. Helminthiasis		

Diseases	New cases	Deaths
214. Intestinal Schistosomiasis		
216. Urinary Schistosomiasis		
218. Guinea worm		
220. Yaws		
222. Leishmaniasis		

IV.4 SURVEILLANCE OF VACCINE PREVENTABLE DISEASES (VPD)		224. Acute Flaccid Paralysis (AFP)	225. Neonatal Tetanus	226. Measles	227. Yellow fever
0-28 days	Cases reported				
	Cases investigated				
	Deaths				
1-11 months	Cases reported				
	Cases investigated				
	Deaths				
12-59 months	Cases reported				
	Cases investigated				
	Deaths				
5-15 years	Cases reported				
	Cases investigated				
	Deaths				
15 years and above	Cases reported				
	Cases investigated				
	Deaths				
Immunization status	Vaccinated				
	Unvaccinated				
	Unknown				

IV.5 SURVEILLANCE OF EPIDEMIC-PRONE DISEASES AND OTHER PUBLIC HEALTH EVENTS

Diseases	New cases	Deaths
228. Meningitis		
230. Cholera		
232. Typhoid Fever		
234. Bloody diarrhea		
236. Dracunculosis		
238. Viral hemorrhagic fevers		
240. Viral Hepatitis B		
242. Viral Hepatitis C		
244. Acute Gastroenteritis		
246. Lymphatic Filariasis		
248. Anthrax		
250. Chikungunya		

Diseases	New cases	Deaths
229. Chickenpox		
231. Genital ulcer (non vesicular)		
233. Plague		
235. Rabies		
237. SRAS (atypical pneumopathy)		
239. Flu Syndrome		
241. Dengue fever		
243. Smallpox		
245. Urethral discharge		
247. Dog bite		
249. Snake bite		
251. Other cases of poisoning		

IV.6 INTEGRATED MANAGEMENT OF ACUTE MALNUTRITION (IMAM)

Age group	Total at the beginning of the month	New Admissions			RE-ADMISSION following Abandonment (< 2 months)	INTERNAL TRANSFER (from ITNC or another ANC)	Total Admissions in the ANC	Transfert INTERNAL TRANSFER (to the ITNC or ANC)	Discharged				Total discharged	Total at month end
		P/T < -3 z-score or PB < 115 mm or PB < 180 mm	CEDEMAS	RELAPSE					CURED	ABANDONMENTS	DEATHS	NOT RESPONDING		
6-59 months														
> 59 months														
TOTAL														
								%	%	%	%	%		

Age group	New admissions		
	Girls	Boys	Total
6-59 months			
> 59 months			

Inputs	In stock	In	Out	Balance
ATPE (sachet)				
Amoxicilline				

Admission errors		
Average duration of stay		

IV.7 HEALTH FACILITY ACTIVITIES

V.1 Consultations / hospitalisations/deaths	Number of cases per age group and gender					
	0 – 59 months		5 years and + (excluding Pregnant women)		Pregnant women	Total
	M	F	M	F		
252. Total number of consultations during the month						
253. Total number of available beds						
254. Total number of hospitalized patients during the month						
255. Total number of hospitalization days during the month						
256. Average duration of hospitalization						
257. Number of patients referred to the upper level during the month						
258. Total number of deaths recorded during the month						
259. Number of death declarations forwarded to the Civil Status Centre during the month						

V.2 The Five main reasons for consultation during the month	Number per age group and gender						
	0 – 59 months		5-14 years		15 years and above		% Total consultations
	M	F	M	F	M	F	
1-							
2-							
3-							
4-							
5-							

V.3 The Five main reasons of hospitalization during the month	Number per age group and gender						
	0 – 59 months		5 -14 years		15 years and above		% total hospitalisations
	M	F	M	F			
1-							
2-							
3-							
4-							
5-							

V.4 The Five main causes of death during the month	Number of deaths per age group and gender						
	0 – 59 months		5 years -14 years		15 years and +		% total deaths
	M	F	M	F			
1-							
2-							
3-							
4-							
5-							

VI- TRACER DRUGS

	Tracer drugs	Stock at the beginning of the month	Quantity received within the month	Quantity used	Momentary assistance / redeployment	Loss	Physical stock available at the end of the month	Number of stockout days	Quantity about to become expired
1.	Nevirapine syrup								
2.	NVP 200 mg + 3TC 150 mg + AZT 300 mg oral form								
3.	Efv 600 mg + 3tc 150 mg + tdf 300 mg oral form								
4.	Injectable Artesunate (Number of ampoules)								
5.	Injectable Artemether (Number of ampoules)								
6.	Artesunate+amodiaquine 100mg/270mg tablet (Number of treatments)								
7.	Artesunate+amodiaquine (25mg/62.5mg or 50mg/135mg) tablet (Number of treatments)								
8.	Sulfadoxine pyrimethamine 500mg /25 mg oral form (Number of tablets)								
9.	Artemether + lumefantrine 20/120 mg (Number of treatments)								
10.	Iron syrup								
11.	Folic acid + Iron (25mg +66 mg) tablet								
12.	Paracetamol 500mg oral form								
13.	Paracetamol 120 mg/5ml syrup vial 100 ml								
14.	Paracetamol 100 mg oral form (Number of tablets)								
15.	Malaria RDT								
16.	Llin								
17.	Oral rehydration salts + zinc oxyde								
18.	Doxycycline 100mg tablet								
19.	Ringer lactate solution 500 cc								
20.	Metronidazole 250 mg tablet								
21.	Metronidazole 125 mg/5ml syrup								
22.	Cotrimoxazole 480 mg tablet								
23.	Cotrimoxazole 240 mg / 5 ml, oral suspension								
24.	Amoxicilline 500mg oral form								

25.	Amoxicilline 250 mg / 5ml, syrup, 60 ml Vial								
26.	Ceftriaxone 1g, injectable ampoule								
27.	Glibenclamide 5mg oral form								
28.	Mebendazole 100 mg/5ml syrup								
29.	Aluminium Hydroxyde 500 mg								
30.	Omeprazole 20mg oral form								
31.	Iodized Polyvidone 10%								
32.	Oxytocin 10 ui/ml, injectable								
33.	Dexamethasone 4 mg injectable								
34.	Tetanus serum								
35.	Anti-venom serum								
36.	Diazepam								
37.	Magnesium Sulfate, 1.5 g/10 ml injectable								
38.	Atropine 0.25 mg tablet								
39.	Fentanyl 100 mg, tablet								
40.	Furosemid 20 mg, injectable								
41.	Ibuprofene 400 mg tablet								
42.	Mebendazole 100 mg, tablet								
43.	Rifampicine + INH+Pyrazinamide + Ethambutol								
44.	Mixtard Human insuline 100 UI/10ml injectable								
45.	<i>Progestative pill</i>								
46.	<i>Oestroprogestogenic pill</i>								
47.	<i>Morning-after pill</i>								
48.	<i>Intramuscular injectable (Depo provera,...)</i>								
49.	<i>Subcutaneous injectable (Sayana Press)</i>								
50.	<i>Implants</i>								
51.	<i>IUD</i>								
52.	<i>Male condom</i>								
53.	<i>Female condom</i>								

VII. EPI INPUTS	Stock at the health facility (dose)			Stock lost (dose)			Stock used (dose of open vials)	Number of stock out days
	Stock at the beginning of the month	Quantity received within the month	Remaining stock at month end	Bad PCV	Frozen	Expired/ Others		
B.C.G.								
OPV								
Hep B								
DPT-HepB +Hib (Penta)								
PNEUMO (PCV 13)								
Rota								
VPI								
RR								
VAA								
MenA								
V.A.T.								
Td								
VPH								
Vit_A 50 000 U.I.								
Vit_A 100 000 U.I.								
Vit_A 200 000 U.I.								
Syringe AB 0,05 ml BCG								
Syringe AB 0,5 ml								
Syringe Dil. 2 ml								
Syringe Dil. 5 ml								
Routine immunisation card								
Safety box								

V. PHARMACO VIGILANCE	
260. Number of side effects reported during the month	
261. Number of serious side effects reported during the month	
262. Number of serious side effects reported and investigated during the month	

VI. COMMUNITY INVOLVEMENT

263. Number of health committee meetings held during the month	
264. Number of management committee meetings held during the month	

VII. HUMAN RESOURCES

Type of staff	Number of staff posted at the HF	Staff available	Retired staff still working
Senior State Registered Nurse			
State Registered Nurse			
Health Technician			
Assistant nurse			
Pharmacy clerk			
Cleaner			
Other staff			
Community health worker			

